Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
Advertising
Report Store
UsernamePublicRestriction
Tags:

Clozaril superiority claim?

  • News

Executive Summary

FDA's Psychopharmacologic Drugs Advisory Committee will review Novartis'Clozaril (clozapine) for treatment of suicidality in patients with schizophrenia or schizoaffective disorders Nov. 4. The review will focus on a head-to-head study versus Lilly's Zyprexa (olanzapine). The meeting will take place at the Holiday Inn, Gaithersburg, Md. [To sign up for a webcast of this meeting, visit 1FDAAdvisoryCommittee.com.]...
Table

View full table

Advertisement
Advertisement
Tags:
UsernamePublicRestriction

Register

PS040536

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By